The Filing Desk

ClearPoint Neuro vs CytoSorbents

ClearPoint Neuro CLPT · CytoSorbents CTSO · Health Care Equipment

CytoSorbents reported revenue of $37 million in fiscal 2025, about the same as ClearPoint Neuro's $37 million in fiscal 2025. ClearPoint Neuro's revenue grew 17.8% in its latest year, and CytoSorbents' grew 4.1%. ClearPoint Neuro had an operating margin of -65.4%, against -39.8% at CytoSorbents. Free cash flow was −$24 million at ClearPoint Neuro and −$13 million at CytoSorbents.

Side by side

ClearPoint NeuroCytoSorbents
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$37M$37M
Revenue growth17.8%4.1%
Revenue growth a year, last 5 years23.7%−2.0%
Gross margin61.4%71.5%
Operating margin−65.4%−39.8%
Net margin−69.1%−22.1%
Free cash flow−$24M−$13M
Free cash flow margin−66.1%−33.8%
Return on capital−104.7%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count4.8%14.3%
Last close$7.31$5.13
P/E at the last close——
Insider trades, last 12 monthssold $2.5 millionbought $269,332, sold $0
Piotroski F-score4 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ClearPoint NeuroCytoSorbents
Operating margin
Percent of revenue
ClearPoint NeuroCytoSorbents
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ClearPoint NeuroCytoSorbents

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ClearPoint Neuro and CytoSorbents pages.